View Item 

Show simple item record

Tegaserod Does not Alter Fasting or Meal-Induced Biliary Tract Motility
dc.contributor.authorFisher, Robert S.en_US
dc.contributor.authorThistle, Johnsonen_US
dc.contributor.authorLembo, Anthonyen_US
dc.contributor.authorNovick, Jamesen_US
dc.contributor.authorO'Kane, Patricken_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorBeglinger, Christophen_US
dc.contributor.authorRueegg, Peteren_US
dc.contributor.authorShi, Victoren_US
dc.contributor.authorDogra, Angelien_US
dc.contributor.authorLuo, Donghamen_US
dc.contributor.authorEarnest, David L.en_US
dc.date.accessioned2010-06-01T20:54:34Z
dc.date.available2010-06-01T20:54:34Z
dc.date.issued2004-07en_US
dc.identifier.citationFisher, Robert S.; Thistle, Johnson; Lembo, Anthony; Novick, James; O'Kane, Patrick; Chey, William D.; Beglinger, Christoph; Rueegg, Peter; Shi, Victor; Dogra, Angeli; Luo, Dongham; Earnest, David L. (2004). "Tegaserod Does not Alter Fasting or Meal-Induced Biliary Tract Motility." The American Journal of Gastroenterology 99(7): 1342-1349. <http://hdl.handle.net/2027.42/74005>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74005
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15233676&dopt=citationen_US
dc.format.extent142057 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rights2004 by the Am. Coll. of Gastroenterologyen_US
dc.titleTegaserod Does not Alter Fasting or Meal-Induced Biliary Tract Motilityen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumTemple University Hospital, Philadelphia; Mayo Clinic, Rochester; Beth Israel Deaconess Hospital, Boston; Charm City Research, Baltimore; Thomas Jefferson University Hospital, Philadelphia; University of Michigan Health Service, Ann Arbor; University Hospital, Basel, Switzerland; Novartis Pharma AG, Basel, Switzerland; and Novartis Pharmaceuticals Corporation, East Hanover, New Jerseyen_US
dc.identifier.pmid15233676en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74005/1/j.1572-0241.2004.30301.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2004.30301.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceGrider JR, Foxx-Orenstein AE, Jin JG. 5-Hydro-xytryptamine 4 receptor agonists initiate the peristaltic reflex in human, rat and guinea pig intestine. Gastroenterology 1988; 115: 370 – 80.en_US
dc.identifier.citedreferencePrather CM, Camilleri M, Zinsmeister AR, et al. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000; 118: 463 – 8.en_US
dc.identifier.citedreferenceDegen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001; 15: 1745 – 51.en_US
dc.identifier.citedreferenceKennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg 2000; 87: 1658 – 63.en_US
dc.identifier.citedreferencevan Erpecum KJ, Venneman NG, Portincasa P, et al. Review article: Agents affecting gall-bladder motility—role in treatment and prevention of gallstones. Aliment Pharmacol Ther 2000; 14 ( suppl 2 ): 66 – 70.en_US
dc.identifier.citedreferencePeeters T, Matthijs G, Depoortere I, et al. Erythromycin is a motilin receptor agonist. Am J Physiol Gastrointest Liver Physiol 1989; 257: G470 – 4.en_US
dc.identifier.citedreferenceCatnach SM, Fairclough PD, Trembath RC, et al. Effect of oral erythromycin on gallbladder motility in normal subjects and subjects with gallstones. Gastroenterology 1992; 102: 2071 – 6.en_US
dc.identifier.citedreferenceDoggrell SA, Scott GW. The occurrence of postsynaptic alpha- and beta-adrenoceptors in the guinea pig gall-bladder. Br J Pharmacol 1980; 71: 185 – 9.en_US
dc.identifier.citedreferenceSengupta S, Cooney R, Baj M, et al. Prokinetic effect of indoramin, an alpha-adrenergic antagonist on human gall-bladder. Aliment Pharmacol Ther 2002; 16 ( 10 ): 1801 – 3.en_US
dc.identifier.citedreferenceHillsley K, Mawe GM. 5-HT is present in nerves of guinea pig sphincter of Oddi and depolarizes sphincter of Oddi neurons. Am J Physiol Gastrointest Liver Physiol 1998; 275 ( 38 ): G1018 – 27.en_US
dc.identifier.citedreferenceMarzio L, DiGiammarco AM, Capone F, et al. Effect of cisapride on human fasting gallbladder volume: A real-time ultrasonographic study. Eur J Clin Pharmacol 1986; 29: 631 – 3.en_US
dc.identifier.citedreferenceZiegenhagen DJ, Heitz W, Kruis W, et al. Cisapride increases gallbladder volume in gallstone patients before and after extracorporeal shock wave lithotripsy. Aliment Pharmacol Ther 1993; 7: 617 – 22.en_US
dc.identifier.citedreferenceThorens J, Schnegg JF, Brignoli R, et al. Effect of cisapride on gallbladder motility after extracorporeal shock-wave lithotripsy. J Hepatol 1995; 22: 333 – 7.en_US
dc.identifier.citedreferenceBaker RA, Saccone GT, Toouli J. Cisapride inhibits motility of the sphincter of Oddi in the Australian possum. Dig Dis Sci 1990; 35: 711 – 5.en_US
dc.identifier.citedreferencevon Kiedrowski R, Huijghebaert S, Raedsch R. Mechanisms of cisapride affecting gallbladder motility. Dig Dis Sci 2001; 46: 939 – 44.en_US
dc.identifier.citedreferencePatankar R, Ozmen MM, Sanderson A, et al. Effect of cisapride on gallbladder emptying and plasma CCK in normal and vagotomized human subjects. Dig Dis Sci 1996; 41: 543 – 8.en_US
dc.identifier.citedreferenceMarzio L. Factors affecting gallbladder motility: Drugs. Dig Liver Dis 2003; 35 ( suppl 3 ): S17 – 9.en_US
dc.identifier.citedreferenceHopman WP, Kerstens PJ, Jansen JB, et al. Effect of graded physiologic doses of cholecystokinin on gallbladder contraction measured by ultrasonography. Determination of threshold, dose-response relationships and comparison with intraduodenal bilirubin output. Gastroenterology 1985; 89: 1242 – 7.en_US
dc.identifier.citedreferenceDodds WJ, Groh WJ, Darweesh RM, et al. Sonographic measurement of gallbladder volume. Am J Roentgenol 1985; 145: 1009 – 11.en_US
dc.identifier.citedreferenceAppel-Dingemanse S, Horowitz A, Campestrini J, et al. The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects: Male and female, elderly and young. Aliment Pharmacol Ther 2001; 15: 937 – 44.en_US
dc.identifier.citedreferenceAppel-Dingemanse S. Clinical pharmacokinetics of tegaserod, a serotonin 5-HT(4) receptor partial agonist with promotile activity. Clin Pharmacokinet 2002; 41: 1021 – 42.en_US
dc.identifier.citedreferenceSwan SK, Zhou H, Horowitz A, et al. Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and healthy subjects. J Clin Pharmacol 2003; 43: 359 – 64.en_US
dc.identifier.citedreferenceSimeone JF, Mueller PR, Ferrucci JT Jr, et al. Sonography of the bile ducts after a fatty meal: an aid in detection of obstruction. Radiology 1982; 143: 211 – 5.en_US
dc.identifier.citedreferenceSherman S, Lehman GA. Sphincter of Oddi dysfunction: Diagnosis and treatment. JOP 2001; 2: 382 – 400.en_US
dc.identifier.citedreferenceElbrond H, Huniche B, Ostergaard L, et al. Oddi's sphincter dysfunction. Ugeskr Laeger 1989; 151: 2507 – 9.en_US
dc.identifier.citedreferenceToouli J. Evaluation of sphincter of Oddi function. Aust N Z J Surg 1989; 59: 445 – 8.en_US
dc.identifier.citedreferenceFein AB, Rauch RF II, Bowie JD, et al. Intravenous cholecystokinin octapeptide: Its effect on the sonographic appearance of the file ducts in normal subjects. Radiology 1984; 153: 499 – 501.en_US
dc.identifier.citedreferencePalasciano G, Serio G, Portincasa P, et al. Gallbladder volume in adults, and relationship to age, sex, body mass index, and gallstones: A sonographic population study. Am J Gastroenterol 1992; 87: 493 – 7.en_US
dc.identifier.citedreferenceGourtsoyiannis NC, Damilakis JE, Charoulakis NZ, et al. Relationship of gallbladder contour, fasting volume and emptying to body size indices in normal subjects and patients with gallstones. Digestion 1995; 56: 395 – 9.en_US
dc.identifier.citedreferenceKern F Jr, Everson GT, DeMark B, et al. Biliary lipids, bile acids, and gallbladder function in the human female. Effects of pregnancy and the ovulatory cycle. J Clin Invest 1981; 68: 1229 – 42.en_US
dc.identifier.citedreferenceXynos E, Haroulakis N, Petrakis I, et al. N. Effect of the menstrual cycle on gallbladder fasting volume and postprandial emptying in nulliparous young females. Invest Radiol 1997; 32: 330 – 4.en_US
dc.identifier.citedreferenceLangaker KJ, Morris D, Pruitt R, et al. The partial 5-HT 4 agonist (HTF 919) improves symptoms in constipation predominant irritable bowel syndrome. Digestion 1998; 59: S3.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2004.30301.x.pdf
Size:
138.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.